Theranexus Société Anonyme (EPA:ALTHX)
France
· Delayed Price · Currency is EUR 0.4390
+0.0090 (2.09%)
May 2, 2025, 5:27 PM CET
Theranexus Société Anonyme Company Description
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease.
The company was founded in 2013 and is headquartered in Lyon, France.
Theranexus Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Mathieu Charvériat |
Contact Details
Address: 60, Avenue Rockefeller Lyon, 69008 France | |
| Phone | 33 1 88 89 70 31 |
| Website | theranexus.com |
Stock Details
| Ticker Symbol | ALTHX |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013286259 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mathieu Charvériat | Co-Founder, Chief Executive Officer and Chairman |
| Julien Veys | Chief Operating Officer and Director |
| Christine Placet | Chief Financial Officer |
| Francoise Vincent-Larrode | Director of Human Resources |
| Marie Sebille | Chief Medical Officer |